

RESEARCH LETTER

Low COAT platelets are frequent in patients with bleeding disorders of unknown cause (BDUC) and can be enhanced by DDAVP

To the Editor,

A large proportion of patients investigated for a mild bleeding tendency remain without a meaningful “diagnostic label” even after comprehensive and repeated laboratory testing.^{1,2} They are currently classified as having a “bleeding disorder of unknown cause” (BDUC)³ and manifest a predominantly mucocutaneous bleeding diathesis, similar to patients diagnosed with mild bleeding disorders. Thus, BDUC patients represent a diagnostic and treatment challenge.²⁻⁴

Accurate quantification of the bleeding phenotype by a validated bleeding assessment tool (BAT) and the clinical gestalt is critical for determining the extent and depth of stepwise laboratory investigations.³ We propose that in selected cases, these should include evaluation of procoagulant COAT platelets by flow cytometry analysis (FCA).⁵ These platelets appear upon combined activation by Collagen And Thrombin, are coated by α -granule proteins retained on their surface by a serotonin- and transglutaminase dependent mechanism,⁶ and are highly efficient in sustaining thrombin generation.⁷ They are also named “coated” platelets⁸ and represent a phenotype of procoagulant platelets.⁹

It is increasingly recognized that procoagulant platelets constitute a pathophysiological relevant component of the hemostatic response.^{10,11} They are generated under static conditions by the combined action of collagen and thrombin and by collagen alone under high shear.⁹ The procoagulant activity develops, after a transient activation of the fibrinogen receptor,^{6,12,13} in those platelets that are capable of increasing their intracellular free calcium into the micromolar range,^{13,14} depolarize mitochondria,¹⁵ and express negatively charged phospholipids on their surface.⁷ These platelets are characterized by a down-regulated fibrinogen receptor^{6,12,13} and a ballooned appearance¹⁶ and are highly procoagulant.⁷

According to our experience, 20%–25% of patients with a high bleeding score but a negative standard laboratory workup (thus satisfying the definition of BDUC³), have an impaired ability to

generate procoagulant COAT platelets. In our first cohort (January 2007–December 2011), we observed low levels of COAT platelets (<20%) in 24% ($n = 16$) of 67 BDUC patients with a clinically significant bleeding diathesis and normal or nondiagnostic light transmission aggregometry (LTA).⁵ Ad hoc analysis of a second cohort (January 2012–March 2017), revealed low COAT platelets (<20%) in 19% ($n = 10$) of 53 BDUC patients.¹⁷

Here, we present original data from our third cohort (January 2015–September 2019). Among 123 adult patients with an unexplained elevated Bleeding assessment tool of the International Society on Thrombosis and Haemostasis (ISTH-BAT) score or bleeding gestalt investigated for a suspected platelet disorder after exclusion of a plasmatic coagulation defect, 37 (30%) had normal ($n = 23$) or nondiagnostic ($n = 14$) LTA and lumiaggregometry (LA), according to established criteria.¹⁸⁻²⁰ Platelets from these BDUC patients³ were further characterized by FCA. Confirming our previous results, we observed a decreased ability to generate COAT platelets (<25%) in 27% ($n = 10$): in four of 14 with nondiagnostic LTA and LA, and in six of 23 with a normal workup. Overall, in our three cohorts we found 36 patients with decreased procoagulant COAT platelets among 157 patients provisionally classified as having BDUC, suggesting a prevalence of 23% (95% confidence interval 20–27).

We believe that it is clinically relevant to identify patients with a decreased ability to generate procoagulant COAT platelets for at least four reasons. First, it is reassuring for the patient and physician to know the reason for an increased bleeding tendency. Second, these patients represent up to 25% of those otherwise diagnosed with BDUC.^{5,17} Third, COAT platelets are clinically relevant (e.g., Prodan and Dale showed that patients with low procoagulant platelets had increased mortality after a hemorrhagic stroke²¹ and an early hemorrhagic transformation after an ischemic stroke).²² Fourth, it is possible to modulate the individual amount of COAT platelets.²³

In patients with primary platelet function defects, we have demonstrated that desmopressin (1-deamino-8-D-arginine vasopressin [DDAVP]) is able to selectively increase procoagulant COAT platelets.²³ This observation has been replicated in patients in whom

Manuscript Handled by: David Lillicrap

Final decision: David Lillicrap, 22 February 2022

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2022 The Authors. *Journal of Thrombosis and Haemostasis* published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis

DDAVP was given because of increased bleeding during cardiac surgery²⁴ and is confirmed by our current experience. In the period from January 2015 to August 2021, we have electively tested DDAVP in 53 adult patients, including primary platelet function defects, von Willebrand disease, or BDUC, finding a relative increase of $\geq 5\%$ COAT platelets in 83% ($n = 44$) of them, as observed in our previous cohort.²³ Currently, we define DDAVP response more stringently as a relative COAT platelet increase of $\geq 10\%$ at one or more time points after DDAVP. This was the case in 74% ($n = 39$) of all patients and 85% ($n = 17$) of 20 with low COAT platelets at baseline previously considered as BDUC. Table 1 highlights that these patients with low procoagulant COAT platelets had a clinically significant bleeding diathesis as expressed by their ISTH-BAT score. Among the 17 patients who responded, COAT platelets progressively increased up to 6 h after DDAVP administration.

The effect of DDAVP on the procoagulant activity of platelets appears to be mediated by increased mobilization of intracellular free sodium (Na^+) and subsequently calcium (Ca^{2+}).^{16,23} Upon activation, although all platelets initially increase their cytosolic Ca^{2+} ,^{13,25} only the subset that activates the reverse mode of the sodium/calcium exchanger,²⁶ which extrudes Na^+ facilitating additional Ca^{2+} influx, will be able to depolarize mitochondria, further increasing cytosolic Ca^{2+} and eventually activating the transmembrane protein TMEM16F.²⁷ This culminates in the transfer of phosphatidylserine and phosphatidylethanolamine from the inner layer of the cell membrane to the outer one.²⁷

The mechanism modulating platelet procoagulant activity appears to be different from the one underlying DDAVP-induced increase of von Willebrand factor (VWF) and factor VIII (FVIII), which depends on cyclic AMP and protein kinase A.²⁸ This is nicely supported by following clinical observation. A 48-year-old woman was referred for our consultation to investigate a clinically significant bleeding diathesis, with an increased ISTH-BAT bleeding score (8 points). Laboratory evaluation showed normal results for VWF, coagulation factors, and fibrinolysis. Repeated LTA/LA were consistent with a signaling defect of the thromboxane A2 receptor.

FCA⁵ showed an impaired secretion of α -granules and a decreased percentage of procoagulant COAT platelets (17%–23%; reference range: 25%–55%, Adler et al. manuscript submitted).

We performed an elective DDAVP test with the standard dose of 0.3 $\mu\text{g}/\text{kg}$ intravenously. VWF, FVIII, and COAT platelets increased by 46%, 51%, and 35% after 2 h, respectively; by 41%, 36%, and 56% after 4 h; and by 32%, 21%, and 137% after 6 h, whereas sodium remained within normal limits. Nevertheless, the patient did not tolerate DDAVP, which had caused an intense headache for 3 days. Because of the clinically relevant bleeding diathesis, the decreased ability to generate procoagulant platelets, and the excellent response observed after the canonical dose,²³ we tested DDAVP at half-dose (0.15 $\mu\text{g}/\text{kg}$) subcutaneously (which is better tolerated than intravenously). Unfortunately, the patient described the same symptoms. Interestingly, although VWF/FVIII remained unaltered, COAT platelets increased again by 15%, 35%, and 41% after 2, 4, and 6 h, respectively. The discordant response of COAT platelets and VWF/FVIII to low DDAVP is consistent with different mechanisms modulating the development of platelet procoagulant activity²⁷ and the secretion of VWF from Weibel-Palade bodies.²⁸ From a practical point of view, this observation may be relevant for patients with a platelet-dependent bleeding diathesis and already high-normal or increased VWF/FVIII values, with a relative contraindication to DDAVP. Further studies should prospectively verify this hypothesis.

In conclusion, we confirm that low procoagulant COAT platelets are frequently found in BDUC patients and we show that DDAVP can enhance their generation. Based on this evidence, we suggest that patients with a clinically relevant bleeding diathesis (based on ISTH-BAT score and/or clinical gestalt) and a negative laboratory workup (including LTA and evaluation of dense granule content/secretion), as indicated by Baker and O'Donnell³ could be investigated by FCA to assess their ability to generate COAT platelets.⁵ Conceptually, this is relevant because procoagulant platelet activity is a known endpoint of platelet activation, differing from and complementing their ability to aggregate^{9–11}—and not detected by conventional platelet function studies.⁵ Clinically, because the proportion of individuals

TABLE 1 The effect of DDAVP on COAT platelet generation in patients with low baseline values

Patients	ISTH-BAT				Procoagulant COAT platelets				
	Number	Females	Age		score		Absolute value, %		
	n (%)	n (%)	Years	IQR	Median	IQR	Median	IQR	
Total	20 (100)	14 (70)	30.9	23.6–49.6	6.5	5–9	Baseline	20.3	17.1–22.0
Responders	17 (85)	12 (71)	33.5	23.6–49.6	7	5–9	Baseline	18.1	17.0–21.2
							After DDAVP	Relative increase, %	
							Hours	Median	IQR
							+2	14.7	10.3–27.3
							+4	24.8	8.6–35.1
+6	38.4	8.0–50.0							

Note: Responders, relative increase of COAT platelets of at least 10% at one or more time points after DDAVP.

Abbreviations: COAT, collagen and thrombin activated platelets; DDAVP, 1-deamino-8-D-arginine vasopressin (= desmopressin); IQR, interquartile range (25th–75th percentiles); ISTH-BAT, Bleeding assessment tool of the International Society on Thrombosis and Haemostasis.

with a decreased ability to generate procoagulant COAT platelets among BDUC patients is relevant^{5,17} and because platelet procoagulant activity can be selectively improved by DDAVP.²³

ACKNOWLEDGMENTS

The authors thank the hemostasis laboratory team (Unité d'Hémostase, Laboratoire d'Hématologie, CHUV, Lausanne, Switzerland) for the help provided with preparing the samples, platelet function studies, and data collection; the bleeding diathesis nurses Ana-Patricia Batista Mesquita Sauvage and Chrystelle Chirlas; the physicians of the Division of Hematology (CHUV, Lausanne) for the clinical care of the patients; and Prof. Dr. med. Michel Duchosal for support. Open Access Funding provided by Université de Lausanne.

CONFLICT OF INTEREST

The authors have no conflicts of interest to declare.

AUTHOR CONTRIBUTIONS

Amandine Segot was in charge of patient care and wrote the manuscript. Marcel Adler was in charge of patient care, performed research, and wrote the manuscript. Alessandro Aliotta performed research and wrote the manuscript. Elena Matthey-Guirao performed research. Michael Nagler performed research. Debora Bertaggia Calderara performed research. Francesco Grandoni was in charge of patient care. Francisco J. Gomez performed research. Lorenzo Alberio supervised clinical and laboratory work, wrote the manuscript. All authors contributed to and approved the final version of the manuscript.

INFORMED CONSENT

This investigation was conducted according to the guidelines of the competent ethical board [Commission cantonale (VD) d'éthique de la recherche sur l'être humain, CER-VD] upon its approval (protocol number CER-VD 2020-00995. Specific patient informed consent for the study was waived, according to the Federal Act on Research involving Human Beings on Human Research (Human Research Act, HRA). However, our centre is using a general research consent for reuse of patient's data. Patients were excluded in case of documented refusal of this general research consent.

FUNDING INFORMATION

A. A. is supported by Research Grants from Dr. Henri Dubois-Ferrière Dinu Lipatti Foundation (2017), Novartis Foundation for Medical-Biological Research (Grant #18B074), and Swiss Heart Foundation (Grant FF19117), and his current salary is partly sustained by SNSF grant 320030-197392. L. A. is supported by a research grant from the Swiss National Science Foundation (SNSF grant 320030-197392).

Amandine Segot¹ 
 Marcel Adler^{1,2}
 Alessandro Aliotta¹ 
 Elena Matthey-Guirao¹ 

Michael Nagler² 
 Debora Bertaggia Calderara¹ 
 Francesco Grandoni¹ 
 Francisco J. Gomez¹ 
 Lorenzo Alberio¹ 

¹Division of Hematology and Central Hematology Laboratory, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland

²Department of Clinical Chemistry, Inselspital, Bern University Hospital, University of Bern (UNIBE), Bern, Switzerland

Correspondence

Amandine Segot, Division of Hematology and Central Hematology Laboratory Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Rue du Bugnon 46, CH-1011 Lausanne, Switzerland.

Email: amandine.segot@chuv.ch; lorenzo.alberio@chuv.ch

ORCID

Amandine Segot  <https://orcid.org/0000-0003-2408-3579>
 Alessandro Aliotta  <https://orcid.org/0000-0002-9382-138X>
 Elena Matthey-Guirao  <https://orcid.org/0000-0003-0395-2384>
 Michael Nagler  <https://orcid.org/0000-0003-4319-2367>
 Debora Bertaggia Calderara  <https://orcid.org/0000-0002-9756-4974>
 Francesco Grandoni  <https://orcid.org/0000-0003-2208-2070>
 Francisco J. Gomez  <https://orcid.org/0000-0002-8816-037X>
 Lorenzo Alberio  <https://orcid.org/0000-0001-9686-9920>

REFERENCES

1. Quiroga T, Mezzano D. Is my patient a bleeder? A diagnostic framework for mild bleeding disorders. *Hematology Am Soc Hematol Educ Program*. 2012;2012:466-474. doi:10.1182/asheducation-2012.1.466
2. Mezzano D, Quiroga T. Diagnostic challenges of inherited mild bleeding disorders: a bait for poorly explored clinical and basic research. *J Thromb Haemost*. 2019;17:257-270. doi:10.1111/jth.14363
3. Baker RI, O'Donnell JS. How I treat bleeding disorder of unknown cause. *Blood*. 2021;138:1795-1804. doi:10.1182/blood.2020010038
4. Thomas W, Downes K, Desborough MJR. Bleeding of unknown cause and unclassified bleeding disorders; diagnosis, pathophysiology and management. *Haemophilia*. 2020;26:946-957. doi:10.1111/hae.14174
5. Daskalakis M, Colucci G, Keller P, et al. Decreased generation of procoagulant platelets detected by flow cytometric analysis in patients with bleeding diathesis. *Cytometry B Clin Cytom*. 2014;86:397-409. doi:10.1002/cyto.b.21157
6. Dale GL, Friese P, Batar P, et al. Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface. *Nature*. 2002;415:175-179.
7. Alberio L, Safa O, Clemetson KJ, Esmon CT, Dale GL. Surface expression and functional characterization of alpha-granule factor V in human platelets: effects of ionophore A23187, thrombin, collagen, and convulxin. *Blood*. 2000;95:1694-1702.
8. Dale GL. Coated-platelets: an emerging component of the procoagulant response. *J Thromb Haemost*. 2005;3:2185-2192. doi:10.1111/j.1538-7836.2005.01274.x

9. Agbani EO, Poole AW. Procoagulant platelets: generation, function, and therapeutic targeting in thrombosis. *Blood*. 2017;130:2171-2179. doi:10.1182/blood-2017-05-787259
10. Heemskerk JW, Mattheij NJ, Cosemans JM. Platelet-based coagulation: different populations, different functions. *J Thromb Haemost*. 2013;11:2-16. doi:10.1111/jth.12045
11. Mazepa M, Hoffman M, Monroe D. Superactivated platelets: thrombus regulators, thrombin generators, and potential clinical targets. *Arterioscler Thromb Vasc Biol*. 2013;33:1747-1752. doi:10.1161/ATVBAHA.113.301790
12. Kulkarni S, Jackson SP. Platelet factor XIII and calpain negatively regulate integrin alphaIIb beta3 adhesive function and thrombus growth. *J Biol Chem*. 2004;279:30697-30706. doi:10.1074/jbc.M403559200
13. Alberio L, Ravanat C, Hechler B, Mangin PH, Lanza F, Gachet C. Delayed-onset of procoagulant signalling revealed by kinetic analysis of COAT platelet formation. *Thromb Haemost*. 2017;117:1101-1114. doi:10.1160/TH16-09-0711
14. Abbasian N, Millington-Burgess SL, Chabra S, Malcor JD, Harper MT. Supramaximal calcium signaling triggers procoagulant platelet formation. *Blood Adv*. 2020;4:154-164. doi:10.1182/bloodadvances.2019000182
15. Remenyi G, Szasz R, Friese P, Dale GL. Role of mitochondrial permeability transition pore in coated-platelet formation. *Arterioscler Thromb Vasc Biol*. 2005;25:467-471.
16. Agbani EO, van den Bosch MT, Brown E, et al. Coordinated membrane ballooning and procoagulant spreading in human platelets. *Circulation*. 2015;132:1414-1424. doi:10.1161/CIRCULATIONAHA.114.015036
17. Adler M, Kaufmann J, Alberio L, Nagler M. Diagnostic utility of the ISTH bleeding assessment tool in patients with suspected platelet function disorders. *J Thromb Haemost*. 2019;17:1104-1112. doi:10.1111/jth.14454
18. Dawood BB, Lowe GC, Lordkipanidzé M, et al. Evaluation of participants with suspected heritable platelet function disorders including recommendation and validation of a streamlined agonist panel. *Blood*. 2012;120:5041-5049. doi:10.1182/blood-2012-07-444281
19. Cattaneo M, Cerletti C, Harrison P, et al. Recommendations for the standardization of light transmission aggregometry: a consensus of the working party from the platelet physiology subcommittee of SSC/ISTH. *J Thromb Haemost*. 2013;11(6):1183-1189. doi:10.1111/jth.12231
20. Badin MS, Graf L, Iyer JK, Moffat KA, Seecharan JL, Hayward CP. Variability in platelet dense granule adenosine triphosphate release findings amongst patients tested multiple times as part of an assessment for a bleeding disorder. *Int J Lab Hematol*. 2016;38:648-657. doi:10.1111/ijlh.12553
21. Prodan CI, Stoner JA, Dale GL. Lower coated-platelet levels are associated with increased mortality after spontaneous intracerebral hemorrhage. *Stroke*. 2015;46:1819-1825. doi:10.1161/STROKEAHA.115.009068
22. Prodan CI, Stoner JA, Cowan LD, Dale GL. Lower coated-platelet levels are associated with early hemorrhagic transformation in patients with non-lacunar brain infarction. *J Thromb Haemost*. 2010;8:1185-1190. doi:10.1111/j.1538-7836.2010.03851.x
23. Colucci G, Stutz M, Rochat S, et al. The effect of desmopressin on platelet function: a selective enhancement of procoagulant COAT platelets in patients with primary platelet function defects. *Blood*. 2014;123:1905-1916. doi:10.1182/blood-2013-04-497123
24. Swieringa F, Lance MD, Fuchs B, et al. Desmopressin treatment improves platelet function under flow in patients with postoperative bleeding. *J Thromb Haemost*. 2015;13:1503-1513. doi:10.1111/jth.13007
25. Aliotta A, Bertaggia Calderara D, Alberio L. Flow cytometric monitoring of dynamic cytosolic calcium, sodium, and potassium fluxes following platelet activation. *Cytometry A*. 2020;97:933-944. doi:10.1002/cyto.a.24017
26. Aliotta A, Bertaggia Calderara D, Zermatten MG, Alberio L. Sodium-calcium exchanger reverse mode sustains dichotomous ion fluxes required for procoagulant COAT platelet formation. *Thromb Haemost*. 2021;121:309-321. doi:10.1055/s-0040-171670
27. Aliotta A, Bertaggia Calderara D, Zermatten MG, Marchetti M, Thrombocytopathies AL. Not just aggregation defects-the clinical relevance of procoagulant platelets. *J Clin Med*. 2021;10:894. doi:10.3390/jcm10050894
28. Kaufmann JE, Vischer UM. Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). *J Thromb Haemost*. 2003;1:682-689. doi:10.1046/j.1538-7836.2003.00190.x